bryostatin 1

Phase 2Small molecule

NNational Cancer Institute (NCI)

bryostatin 1 is one of 563 small molecule programs targeting HIV infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

562

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

Kidney CancerActive, not recruiting

Esophageal CancerActive, not recruiting

LymphomaActive, not recruiting

Head and Neck Malignant NeoplasiaActive, not recruiting

LeukemiaActive, not recruiting

Alzheimer DiseaseActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Plasma Cell NeoplasmActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

HIV InfectionPhase 1

Active, not recruiting

Kidney CancerPhase 2

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Head and Neck Malignant NeoplasiaPhase 2

Active, not recruiting

LeukemiaPhase 2

Active, not recruiting

Alzheimer DiseasePhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Plasma Cell NeoplasmPhase 2

Active, not recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

bryostatin 1

NNational Cancer Institute (NCI)

Phase 2

1 2

Lexiscan

Astellas

Preclinical

1 3

Adenocard

Astellas

Preclinical

1 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 5

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 6

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 7

Bisphosphonate

Amgen

Preclinical

2 8

Tianeptine

Pfizer

Preclinical

1 9

Citalopram Hydrobromide

TTorrent Pharmaceuticals Limited

Preclinical

1 10

Ibrance

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Statin

NCT06190912

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia4 trials

Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma

Completed·VVirginia Commonwealth University·Phase 1·NCT00005580·54 enrolled

Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT00003174·80 enrolled

Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002908

Show 1 more trial

Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·NNational Institute on Aging (NIA)·Phase 2·NCT00087425·48 enrolled

Lymphoma4 trials

Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00058305·28 enrolled

Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00022555·12 enrolled

Bryostatin-1 in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00002725·35 enrolled

Show 1 more trial

Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

Completed·NNational Institute on Aging (NIA)·Phase 1·NCT00003993·24 enrolled

Kidney Cancer4 trials

Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00032188·65 enrolled

Bryostatin 1 In Treating Patients With Progressive Kidney Cancer

Completed·CCancer Research UK·Phase 2·NCT00005056

Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00003968·35 enrolled

Show 1 more trial

Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer

Completed·VVirginia Commonwealth University·Phase 1·NCT00006022·17 enrolled

Advanced Cancer3 trials

Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced Cancer

Completed·LLombardi Comprehensive Cancer Center·Phase 1·NCT00003108

Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT00004144·36 enrolled

Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix

Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT00005965

Alzheimer's Disease3 trials

Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease

Terminated·NNeurotrope Bioscience, Inc.·Phase 1/2·NCT02221947·9 enrolled

Bryostatin Treatment of Moderately Severe Alzheimer's Disease

Completed·NNeurotrope Bioscience, Inc.·Phase 2·NCT04538066·122 enrolled

A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease

Completed·NNeurotrope Bioscience, Inc.·Phase 2·NCT02431468·147 enrolled

22 more indications

Leukemia2 trials

Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia

Completed·VVirginia Commonwealth University·Phase 2·NCT00017342

Bryostatin 1 and High Dose Cytarabine in Treating Patients With Refractory or Relapsed Leukemia or Lymphoma

Completed·VVirginia Commonwealth University·Phase 1·NCT00003079·30 enrolled

Myelodysplastic Syndrome2 trials

Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00003171

A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Completed·—·Phase 2·NCT00136461·40 enrolled

Unresectable Cancer1 trial

Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer

Completed·NNYU Langone Health·Phase 1·NCT00003132

Primary Peritoneal Cancer1 trial

Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006942·32 enrolled

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00012376·35 enrolled

Non-Small Cell Lung Cancer1 trial

Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00005849·15 enrolled

Recurrent Head and Neck Cancer1 trial

Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003443

Pancreatic Cancer1 trial

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00031694·19 enrolled

Metastatic Prostate Cancer1 trial

Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00005028·46 enrolled

Metastatic Colorectal Cancer1 trial

Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00003220

B-cell Malignancies1 trial

Bryostatin and Vincristine in B-Cell Malignancies

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003166·18 enrolled

Breast Cancer1 trial

Bryostatin 1 in Treating Patients With Stage IV Breast Cancer

Completed·UUniversity of Colorado, Denver·Phase 2·NCT00003205

Metastatic Solid Tumors1 trial

Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00112476·24 enrolled

Statin1 trial

Safety of Bryostatin in Patients With MS

Active, not recruiting·RRobert Fox·Phase 1·NCT06190912·20 enrolled

Ovarian Epithelial Cancer1 trial

Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer

Completed·UUniversity of Glasgow·Phase 2·NCT00004008

Stomach Cancer1 trial

Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00006389·12 enrolled

Locally Advanced1 trial

Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00006081·37 enrolled

Patients With Advanced Solid Tumors1 trial

Bryostatin 1 Plus Paclitaxel and Cisplatin in Treating Patients With Advanced Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003242

Esophageal Cancer1 trial

Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00005599

Antiretroviral Treatment1 trial

Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment

Completed·FFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal·Phase 1·NCT02269605·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 42 trial records for bryostatin 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — bryostatin 1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for bryostatin 1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

bryostatin 1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Chronic Lymphocytic Leukemia4 trials

Lymphoma4 trials

Kidney Cancer4 trials

Advanced Cancer3 trials

Alzheimer's Disease3 trials

Leukemia2 trials

Myelodysplastic Syndrome2 trials

Unresectable Cancer1 trial

Primary Peritoneal Cancer1 trial

Recurrent or Refractory1 trial

Multiple Myeloma1 trial

Chemotherapy1 trial

Non-Small Cell Lung Cancer1 trial

Recurrent Head and Neck Cancer1 trial

Pancreatic Cancer1 trial

Metastatic Prostate Cancer1 trial

Metastatic Colorectal Cancer1 trial

B-cell Malignancies1 trial

Breast Cancer1 trial

Metastatic Solid Tumors1 trial

Statin1 trial

Ovarian Epithelial Cancer1 trial

Stomach Cancer1 trial

Locally Advanced1 trial

Patients With Advanced Solid Tumors1 trial

Esophageal Cancer1 trial

Antiretroviral Treatment1 trial

References

Drug Info

Quick Facts

Related News